GlassScriptPhysician profile
Jason A Cohen
NPI 1942588447
$2,762.01
in general payments reported to CMS, 2019-2025
20 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $297 · 2020: $46.70 · 2021: $244 · 2022: $358 · 2023: $648 · 2024: $609 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,816.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,816.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $350.86 | 2022-2025 | Ingrezza, Ongentys |
| Mdd US Operations, LLC | $349.97 | 2023-2025 | Gocovri, Gocovri, Apokyn |
| Kyowa Kirin, INC. | $282.49 | 2020-2023 | Nourianz |
| Abbvie INC. | $273.44 | 2023-2025 | Botox, Duopa |
| Acorda Therapeutics, INC | $255.77 | 2019-2024 | Inbrija |
| Teva Pharmaceuticals USA, INC. | $241.07 | 2021-2025 | Austedo Xr, Austedo Xr, Austedo |
| Catalyst Pharmaceuticals, INC. | $180.39 | 2022-2025 | Firdapse |
| Adamas Pharmaceuticals, INC. | $173.38 | 2019-2021 | |
| Sunovion Pharmaceuticals INC. | $113.73 | 2021-2022 | |
| Lundbeck LLC | $112.26 | 2019 | |
| Acadia Pharmaceuticals INC | $98.53 | 2023-2025 | Nuplazid |
| Ipsen Biopharmaceuticals, INC | $94.69 | 2024-2025 | Dysport |
| Boston Scientific Corporation | $45.31 | 2024-2025 | Compliance Endokit, Acquire |
| Vertical Pharmaceuticals, LLC | $35.03 | 2019 | |
| Alnylam Pharmaceuticals INC. | $29.82 | 2021 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amneal Pharmaceuticals LLC | $29.71 | 2023 | Rytary |
| Greenwich Biosciences, INC. | $28.38 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $24.70 | 2023 | |
| Alexion Pharmaceuticals, INC. | $22.91 | 2022 | |
| Avion Pharmaceuticals | $19.57 | 2023 | Dhivy |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jason Cohen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.